SCHEMBL10101202

SCHEMBL10101202

C[C@@H](c1ccc(OC(=O)OC(C)(C)C)cc1F)[C@H](NC(=O)OC(C)(C)C)C(=O)N1CCC(F)(F)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 6/20 0.36
HRH1 P35367 6/20 0.36
TRPA1 O75762 1/20 0.35
KDM1A O60341 1/20 0.34
DPP4 P27487 4/20 0.34
DPP7 Q9UHL4 4/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
KCNH2 Q12809 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
S1PR2 O95136 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL865096 0.87 TRPA1 (0.37) HRH2HRH1TRPA1DPP4DPP7
SCHEMBL865095 0.87 TRPA1 (0.37) HRH2HRH1TRPA1DPP4DPP7
SCHEMBL865128 0.87 DPP4 (0.36) HRH2HRH1TRPA1DPP4DPP7
SCHEMBL865127 0.87 DPP4 (0.36) HRH2HRH1TRPA1DPP4DPP7
SCHEMBL864646 0.81 TRPA1 (0.41) TRPA1KDM1AKDM4EGLAGAA
SCHEMBL8076548 0.80 HRH2 (0.38) HRH2HRH1DPP4DPP7KCNH2
SCHEMBL865257 0.80 MAPT (0.41) TRPA1KDM1AALDH1A1KDM4EGLA
SCHEMBL3696786 0.80 GPR119 (0.50)
SCHEMBL2891416 0.80 GPR119 (0.50)
SCHEMBL8276053 0.76 DPP4 (0.40) HRH2HRH1DPP4DPP7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077793-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-29 US disclosed
US-20120077793-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077793-A1 Compounds for the Treatment of Metabolic Disorders GPR119, GPR132, FFAR2 HRH2 647/4885HRH1 1176/4885TRPA1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.